PhaseII trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operatible gastrointestinal stromal tumor (GIST) : early results of RTOG 0132/ACRIN 6665

収録刊行物

• J Surg Oncol

  J Surg Oncol 99 42-47, 2009